Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
Identifieur interne : 000942 ( Ncbi/Curation ); précédent : 000941; suivant : 000943Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
Auteurs : G-Y R. Hsiung [Canada] ; S K Das ; R. Ranawaya ; A-L Lafontaine ; O. SuchowerskySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), British Columbia, Dose-Response Relationship, Drug, Drug Resistance, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Long-Term Care, Male, Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Patient Satisfaction, Retrospective Studies, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- chemical , adverse effects : Botulinum Toxins, Type A.
- geographic : British Columbia.
- drug therapy : Movement Disorders.
- etiology : Movement Disorders.
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Resistance, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Long-Term Care, Male, Middle Aged, Patient Satisfaction, Retrospective Studies, Treatment Outcome.
Abstract
Although botulinum toxin A (BTX) has been licensed in Canada for treatment of various movement disorders since 1990, few clinical studies regarding its long-term efficacy and side effects have been reported. We conducted a retrospective analysis of 235 patients who received BTX from our movement disorders clinic over a 10-year period (January 1990 to December 1999). A total of 2,616 treatment cycles (multiple injections) were administered to 235 patients with cervical dystonia (CD), hemifacial spasm (HS), blepharospasm (BP), and other movement disorders. Substantial benefit at 5 years was seen in most patients (90% in BP, 88% in HS, 63% in CD, 100% in jaw closing and lower limb dystonia, and 56% in writer's cramp). Benefit was maintained for up to 10 years in CD, HS, and BP data, with a 75.8% benefit reported. Twenty-eight percent of patients discontinued treatment during the follow-up period due to a variety of reasons. Of these, 9.1% of patients developed primary resistance, and 7.5% of patients secondary resistance. Adverse effects, mostly minor, developed in 27% of patients at any one time, occurring over 4.5% of treatment cycles. These were most frequently reported in blepharospasm (22 of 36 patients in 40 cycles), followed by hemifacial spasm (21 of 70 patients in 46 cycles), and cervical dystonia (17 of 106 in 28 cycles). Only 1.3% of patients discontinued therapy due intolerable adverse effects. The results show that BTX is a safe and effective treatment of various types of movement disorders, and most side effects are well tolerated. Discontinuation for any reason was also low after 5 years. Efficacy was maintained after long periods of treatment with high degree of patient satisfaction.
DOI: 10.1002/mds.10252
PubMed: 12465070
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003909
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003909
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003A34
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000942
Links to Exploration step
pubmed:12465070Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.</title><author><name sortKey="Hsiung, G Y R" sort="Hsiung, G Y R" uniqKey="Hsiung G" first="G-Y R" last="Hsiung">G-Y R. Hsiung</name><affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Clinic, Department of Clinical Neurosciences at University of Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Clinic, Department of Clinical Neurosciences at University of Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Das, S K" sort="Das, S K" uniqKey="Das S" first="S K" last="Das">S K Das</name></author><author><name sortKey="Ranawaya, R" sort="Ranawaya, R" uniqKey="Ranawaya R" first="R" last="Ranawaya">R. Ranawaya</name></author><author><name sortKey="Lafontaine, A L" sort="Lafontaine, A L" uniqKey="Lafontaine A" first="A-L" last="Lafontaine">A-L Lafontaine</name></author><author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O" last="Suchowersky">O. Suchowersky</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12465070</idno><idno type="pmid">12465070</idno><idno type="doi">10.1002/mds.10252</idno><idno type="wicri:Area/PubMed/Corpus">003909</idno><idno type="wicri:Area/PubMed/Curation">003909</idno><idno type="wicri:Area/PubMed/Checkpoint">003A34</idno><idno type="wicri:Area/Ncbi/Merge">000942</idno><idno type="wicri:Area/Ncbi/Curation">000942</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.</title><author><name sortKey="Hsiung, G Y R" sort="Hsiung, G Y R" uniqKey="Hsiung G" first="G-Y R" last="Hsiung">G-Y R. Hsiung</name><affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Clinic, Department of Clinical Neurosciences at University of Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Clinic, Department of Clinical Neurosciences at University of Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Das, S K" sort="Das, S K" uniqKey="Das S" first="S K" last="Das">S K Das</name></author><author><name sortKey="Ranawaya, R" sort="Ranawaya, R" uniqKey="Ranawaya R" first="R" last="Ranawaya">R. Ranawaya</name></author><author><name sortKey="Lafontaine, A L" sort="Lafontaine, A L" uniqKey="Lafontaine A" first="A-L" last="Lafontaine">A-L Lafontaine</name></author><author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O" last="Suchowersky">O. Suchowersky</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (adverse effects)</term><term>British Columbia</term><term>Dose-Response Relationship, Drug</term><term>Drug Resistance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Injections, Intramuscular</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Patient Satisfaction</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>British Columbia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Dose-Response Relationship, Drug</term><term>Drug Resistance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Injections, Intramuscular</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Patient Satisfaction</term><term>Retrospective Studies</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although botulinum toxin A (BTX) has been licensed in Canada for treatment of various movement disorders since 1990, few clinical studies regarding its long-term efficacy and side effects have been reported. We conducted a retrospective analysis of 235 patients who received BTX from our movement disorders clinic over a 10-year period (January 1990 to December 1999). A total of 2,616 treatment cycles (multiple injections) were administered to 235 patients with cervical dystonia (CD), hemifacial spasm (HS), blepharospasm (BP), and other movement disorders. Substantial benefit at 5 years was seen in most patients (90% in BP, 88% in HS, 63% in CD, 100% in jaw closing and lower limb dystonia, and 56% in writer's cramp). Benefit was maintained for up to 10 years in CD, HS, and BP data, with a 75.8% benefit reported. Twenty-eight percent of patients discontinued treatment during the follow-up period due to a variety of reasons. Of these, 9.1% of patients developed primary resistance, and 7.5% of patients secondary resistance. Adverse effects, mostly minor, developed in 27% of patients at any one time, occurring over 4.5% of treatment cycles. These were most frequently reported in blepharospasm (22 of 36 patients in 40 cycles), followed by hemifacial spasm (21 of 70 patients in 46 cycles), and cervical dystonia (17 of 106 in 28 cycles). Only 1.3% of patients discontinued therapy due intolerable adverse effects. The results show that BTX is a safe and effective treatment of various types of movement disorders, and most side effects are well tolerated. Discontinuation for any reason was also low after 5 years. Efficacy was maintained after long periods of treatment with high degree of patient satisfaction.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000942 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000942 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:12465070
|texte= Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:12465070" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |